课题基金 / 基金详情

Vectorized scFv antibodies to treat tau pathology in Alzheimers disease enhancing epitope targeting and delivery strategies

Vectorized scFv antibodies to treat tau pathology in Alzheimers disease enhancing epitope targeting and delivery strategies
用于治疗阿尔茨海默病中 tau 病理的矢量化 scFv 抗体增强表位靶向和递送策略
批准号:
10730122
负责人:
Cristina d'Abramo
金额:
$20.74万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-15 至 2025-05-31

项目摘要

项目成果

Cristina d'Abramo的其他基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT Increasing evidence supports the existence of tau as an extracellular protein, and the concept of its trans-cellular propagation as a mechanism for the initiation and progression of Alzheimer's disease (AD). In this context, using antibodies to target tau pathology appears as an appropriate approach to clear neurofibrillary tangles in AD models. In preclinical models, conventional tau immunotherapy has achieved only incomplete clearance of tau pathology and presents limitations in terms of potential inflammatory adverse events, long-term sustainability, compliance and costs. Also, effective blood brain barrier penetration and choice of the correct tau epitope are still subject of an open debate. In clinical trials, several antibodies directed against tau’s N-terminus did not exert any benefit in participants with prodromal/early onset AD or other tauopathies, raising the question as to whether the antibodies in use are engaging the right epitope of tau at the right time. Some recent studies have demonstrated, in in vitro and preclinical models, the advantage of targeting central-tau epitopes in preventing tau seeding and propagation. In this supplement application, we will apply our extensive experience in the generation and handling of anti-tau monoclonal antibodies and their recombinant variants in the context of immunotherapy. Here we propose to generate new anti-tau antibodies, sequence, and turn them into scFv with the intent to broaden the tau immunotherapy-pipeline.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vectorized scFv antibodies to treat tau pathology in Alzheimer's disease: enhancing epitope targeting and delivery strategies
Vectorized scFv antibodies to treat tau pathology in Alzheimer's disease: enhancing epitope targeting and delivery strategies
Vectorized scFv antibodies to treat tau pathology in Alzheimer's disease: enhancing epitope targeting and delivery strategies
Immunotherapy in Alzheimer's Disease Animal Models Using Tau Recombinant Antibodies